bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1-8 from Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies
Authors: Evans Elizabeth E. , Jonason Alan S. , Bussler Holm , Torno Sebold , Veeraraghavan Janaki , Reilly Christine , Doherty Michael A. , Seils Jennifer , Winter Laurie A. , Mallow Crystal , Kirk Renee , Howell Alan , Giralico Susan , Scrivens Maria , Klimatcheva Katya , Fisher Terrence L. , Bowers William J. , Paris Mark , Smith Ernest S. , Zauderer Maurice
Published: April 2023

Supplementary Figure S1: SEMA4D and PLXNB1 are highly expressed in human cancer. Supplementary Figure S2: SEMA4D gradient at tumor leading edge. Supplementary Figure S3: Tumor volumes of mice selected for immune cell characterization and functional assays. Supplementary Figure S4: CD8+ T cells are required for anti-SEMA4D induced specific immune memory response to Colon26. Supplementary Figure S5: Anti-SEMA4D treatment increases the Teff:Treg ratio. Supplementary Figure S6: Minimal effective dose of MAb67 is ~ 3 mg/kg corresponds with cSEMA4D T cell saturation as a PD marker Supplementary Figure S7: Single agent anti-SEMA4D is highly effective, while immune checkpoint inhibitor antibodies are ineffective in mammary carcinoma model. Supplementary Figure S8: Proposed mechanisms of action for SEMA4D blockade.
Supplementary Figure 2 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Authors: Griesinger Andrea M. , Josephson Rebecca J. , Donson Andrew M. , Mulcahy Levy Jean M. , Amani Vladimir , Birks Diane K. , Hoffman Lindsey M. , Furtek Steffanie L. , Reigan Phillip , Handler Michael H. , Vibhakar Rajeev , Foreman Nicholas K.
Published: April 2023

STAT3, IL-6 and inflammatory response pathway signaling associated gene expression is upregulated in Group A EPN.
Supplementary Figures 1 through 4 from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells
Authors: Peters Haley L. , Tripathi Satyendra C. , Kerros Celine , Katayama Hiroyuki , Garber Haven R. , St. John Lisa S. , Federico Lorenzo , Meraz Ismail M. , Roth Jack A. , Sepesi Boris , Majidi Mourad , Ruisaard Kathryn , Clise-Dwyer Karen , Roszik Jason , Gibbons Don L. , Heymach John V. , Swisher Stephen G. , Bernatchez Chantale , Alatrash Gheath , Hanash Samir , Molldrem Jeffrey J.
Published: April 2023

Supplementary Figure S1. Lung cancer cell lines do not express NE and P3 gene transcripts. Supplementary Figure S2. CTL proliferate in the presence of NE-exposed lung cancer cells. Supplementary Figure S3. HLA class I presentation of mutant neoantigens is enhanced by NE and P3. Supplementary Figure S4. Immunoproteasome expression by lung cancer cells is unaltered by serine proteases.
Supplementary Tables 1 through 4 from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Authors: De Velasco Guillermo , Je Youjin , Bossé Dominick , Awad Mark M. , Ott Patrick A. , Moreira Raphael B. , Schutz Fabio , Bellmunt Joaquim , Sonpavde Guru P. , Hodi F. Stephen , Choueiri Toni K.
Published: April 2023

4 tables included. FDA Approvals for ICIs. Common Terminology Criteria for Adverse Events V4.0. for selected irAEs. Additional subanalysis.
Supplementary Figure Legends from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells
Authors: Peters Haley L. , Tripathi Satyendra C. , Kerros Celine , Katayama Hiroyuki , Garber Haven R. , St. John Lisa S. , Federico Lorenzo , Meraz Ismail M. , Roth Jack A. , Sepesi Boris , Majidi Mourad , Ruisaard Kathryn , Clise-Dwyer Karen , Roszik Jason , Gibbons Don L. , Heymach John V. , Swisher Stephen G. , Bernatchez Chantale , Alatrash Gheath , Hanash Samir , Molldrem Jeffrey J.
Published: April 2023

Figure Legends for Supplementary Figures S1-S4.
Supplementary Methods, Figure Legends from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Methods, Figure Legends
Supplementary Figure S3 from Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Authors: Chu Yaya , Hochberg Jessica , Yahr Ashlin , Ayello Janet , van de Ven Carmella , Barth Matthew , Czuczman Myron , Cairo Mitchell S.
Published: April 2023

Supplementary Fig.S3: U-698-M stimulates the expression of activating receptors on mock exPBNK and CAR exPBNK similarly The expanded NK cells were nucleofected with anti-CD20 CAR mRNA (CAR) or without anti-CD20 CAR mRNA (mock). MOCK exPBNK or CAR exPBNK cells were cultured with medium only, or CD20+ U-698-M at a 3:1 ratio overnight. The activating receptors (NKp30, NKp44, CD69, and NKG2D) and inhibitor receptors (CD94 and KIR2DL2/3) as indicated on MOCK exPBNK and CAR exPBNK were examined and compared by flow cytometry analysis.
Supplementary Figure Legends, Figures 1 - 7 from Fine-tuning Tumor Immunity with Integrin Trans-regulation
Authors: Cantor Joseph M. , Rose David M. , Slepak Marina , Ginsberg Mark H.
Published: April 2023

Supplemental Figure 1. Generation of the α4(S998A) mouse. Supplemental Figure 2. (A) Hematological analysis. B) Na?ve lymphoid organ lymphocyte subsets. C) Humoral immune response. Supplemental Figure 3. Intrinsic homing advantage of α4(S998A) splenocytes. Supplemental Figure 4. Migration of α4(S998A lymphocytes in vitro. Supplemental Figure 5. Lewis Lung Carcinoma Tumor Growth. Supplemental Figure 6. Tumor growth after depletion of lymphoid cells in α4(S988A) mice. Supplemental Figure 7. Migration of α4(S998A) macrophages.
Supplementary Table 3 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Kinetics of IDO1 expression during LPS-induced DC maturation in vitro.
Supplementary Figure 6 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

IDO1 gene expression in common human malignancies.
Supplementary Figures 1 and 2 from Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells
Authors: Van Lint Sandra , Renmans Dries , Broos Katrijn , Goethals Lode , Maenhout Sarah , Benteyn Daphné , Goyvaerts Cleo , Du Four Stephanie , Van der Jeught Kevin , Bialkowski Lukasz , Flamand Véronique , Heirman Carlo , Thielemans Kris , Breckpot Karine
Published: April 2023

Supplementary Fig. S1. Delivery of TriMix mRNA to the tumor reprograms TiDCs. Supplementary Fig. S2. Delivery of TriMix mRNA to tumors induces tumor-specific CTLs.
Supplemental Figure 3 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Authors: Higuchi Tomoe , Flies Dallas B. , Marjon Nicole A. , Mantia-Smaldone Gina , Ronner Lukas , Gimotty Phyllis A. , Adams Sarah F.
Published: April 2023

PARP inhibition and CTLA-4 mAb combination therapy is ineffective against a BRCAwt cancer.
Supplementary Figure 3 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

In vitro characterization of IDO1-expressing DCs.
Supplemental Figure 1 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Authors: Higuchi Tomoe , Flies Dallas B. , Marjon Nicole A. , Mantia-Smaldone Gina , Ronner Lukas , Gimotty Phyllis A. , Adams Sarah F.
Published: April 2023

Treatment diagram for the combination therapy protocol.
Supplementary Figure 1 from Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Authors: Théate Ivan , van Baren Nicolas , Pilotte Luc , Moulin Pierre , Larrieu Pierre , Renauld Jean-Christophe , Hervé Caroline , Gutierrez-Roelens Ilse , Marbaix Etienne , Sempoux Christine , Van den Eynde Benoît J.
Published: April 2023

Characterization and specificity of anti-IDO1 antibodies by Western blot and immunohistochemistry.
Supplementary Tables from Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
Authors: Green Andrew R. , Aleskandarany Mohammed A. , Ali Reem , Hodgson Eleanor Grace , Atabani Suha , De Souza Karen , Rakha Emad A. , Ellis Ian O. , Madhusudan Srinivasan
Published: April 2023

Supplementary Table S1: Clinicopathological characteristics of Nottingham Tenovus series Supplemental Table S2: Clinicopathological characteristics of ER- cohort Supplementary Table S3: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S4: Clinicopathological significance of ATM expression in CD8+ TILs positive and CD8+ TILs negative breast cancer Supplementary Table S5: Clinicopathological significance of BRCA1 expression in CD8 positive and CD8 negative breast cancer Supplementary Table S6: Clinicopathological significance of XRCC1 expression in CD8 positive and CD8 negative breast cancers Supplementary Table S7: Clinicopathological significance of ATM expression in FOXP3 positive and FOXP3negative breast cancer Supplementary Table S8: Clinicopathological significance of BRCA1 expression in FOXP3 positive and FOXP3negative breast cancer Supplementary Table S9: Clinicopathological significance of XRCC1 expression in FOXP3 positive and FOXP3negative breast cancer
Supplementary Figure 5 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Gating strategy for CD8+ T-cell subsets. CM: Central memory; EM: Effector memory; TEMRA: Effector memory expressing CD45RA
Supplementary Figure 4 from Exome Sequencing to Predict Neoantigens in Melanoma
Authors: Pritchard Antonia L. , Burel Julie G. , Neller Michelle A. , Hayward Nicholas K. , Lopez J. Alejandro , Fatho Martina , Lennerz Volker , Wölfel Thomas , Schmidt Christopher W.
Published: April 2023

Whole -exome alignment of PABPC3 compared to the PABPC1 sequence (A): PABPC3 sequencing reads alignment with PABPC1 and PABPC3 reference sequence. (B): PABPC3 dinucleotide change resulting in R -->Q amino acid change in the protein sequence.
Supplementary Tables 1 through 5 from Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers
Authors: Noonepalle Satish K. , Gu Franklin , Lee Eun-Joon , Choi Jeong-Hyeon , Han Qimei , Kim Jaejik , Ouzounova Maria , Shull Austin Y. , Pei Lirong , Hsu Pei-Yin , Kolhe Ravindra , Shi Fang , Choi Jiseok , Chiou Katie , Huang Tim H.M. , Korkaya Hasan , Deng Libin , Xin Hong-Bo , Huang Shuang , Thangaraju Muthusamy , Sreekumar Arun , Ambs Stefan , Tang Shou-Ching , Munn David H. , Shi Huidong
Published: April 2023

Supplementary Table 1: List of primers used for quantitative real time PCR. Supplementary Table. 2: List of primers used for construction of pGL2 and pMIR reporter plasmids. Supplementary Table. 3: List of primers used to generate PCR amplicons for pyrosequencing analysis. Supplementary Table. 4: Sequencing primers used for pyrosequencing. Supplementary Table. 5: Primers used for qPCR analysis in ChIP assay.
Supplementary Figure 8 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Bivariate analysis of tumor stage with vascular invasion and cellular differentiation.
Supplementary Figure 5 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Bivariate analysis of TIL pattern and tumor stage, cellular differentiation, and vascular invasion.
Supplementary Figures S1~S5 from Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Authors: Yang Yaewon , Lim Okjae , Kim Tae Min , Ahn Yong-Oon , Choi Hana , Chung Hyejin , Min Bokyung , Her Jung Hyun , Cho Sung Yoo , Keam Bhumsuk , Lee Se-Hoon , Kim Dong-Wan , Hwang Yu Kyeong , Heo Dae Seog
Published: April 2023

Supplementary Figure S1. Clinical treatment protocol; Supplementary Figure S2. Characterization of ex vivo-expanded NK cells; Supplementary Figure S3. Analysis of donor KIR genotype and clinical outcome; Supplementary Figure S4. Kinetics of donor NK cells in the peripheral blood of recipients; Supplementary Figure S5. NKG2D expression on NK and T cells in patients' peripheral blood.
Supplementary Figure 2 from Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
Authors: Gabrielson Andrew , Wu Yunan , Wang Hongkun , Jiang Jiji , Kallakury Bhaskar , Gatalica Zoran , Reddy Sandeep , Kleiner David , Fishbein Thomas , Johnson Lynt , Island Eddie , Satoskar Rohit , Banovac Filip , Jha Reena , Kachhela Jaydeep , Feng Perry , Zhang Tiger , Tesfaye Anteneh , Prins Petra , Loffredo Christopher , Marshall John , Weiner Louis , Atkins Michael , He Aiwu Ruth
Published: April 2023

Example of computer-assisted evaluation of infiltrate densities.
Supplementary Movie 2 from Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules
Authors: Schmittnaegel Martina , Levitsky Victor , Hoffmann Eike , Georges Guy , Mundigl Olaf , Klein Christian , Knoetgen Hendrik
Published: April 2023

Time-lapse fluorescence microscopy of CMV-pp65-specific T cell mediated killing of MCSP+ tumor cells (Colo38) incubated with 15nM of EBV-pMHCI-IgG as control. Constructs are indicated in the respective panel. T cells are stained in red (PKH-26, Sigma), tumor cells in green (CMFDA, LifeTechnologies). Effector to target ratio was 3:1. Real-time is indicated in the lower left corner in h:m:s:ms (h=hours, m=minutes, s=seconds, ms=milliseconds), scale bar is shown in the lower right corner 0-50 µm (µm=micrometre).
Suppl Figure 1 from Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
Authors: Solomon Benjamin , Young Richard J. , Bressel Mathias , Urban Damien , Hendry Shona , Thai Alesha , Angel Christopher , Haddad Afaf , Kowanetz Marcin , Fua Tsien , Corry June , Fox Stephen , Rischin Danny
Published: April 2023

Scoring Method
Supplementary Figures and Legends from TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells
Authors: Zahm Christopher D. , Colluru Viswa T. , McIlwain Sean J. , Ong Irene M. , McNeel Douglas G.
Published: April 2023

Supplementary Figures and Legends
Figure S1 from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy
Authors: Doorduijn Elien M. , Sluijter Marjolein , Salvatori Daniela C. , Silvestri Serenella , Maas Saskia , Arens Ramon , Ossendorp Ferry , van der Burg Sjoerd H. , van Hall Thorbald
Published: April 2023

Effect of Aldara on immune cell activation and in other tumor models
Supplementary Figure S5. ADU-S100 induces global changes in cytokine and chemokine production in the TME of non-tolerant, tumor-bearing FVB/N mice. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

At 24 hours post IT injection of ADU-S100 or HBSS, cytokine and chemokine production within the TME of non-tumor bearing FVB/N mice were evaluated by ELISA. (A) Significant amounts of TNFα and IL-6 were produced in the TME in response to ADU-S100. (B) Significant amounts of CCL2, CCL5, and CCL11 were produced in the TME in response to ADU-S100. (C) Significant amounts of CXCL1 were produced in the TME in response to ADU-S100, whereas CXCL9 and CXCL10 were already highly expressed independent of ADU-S100 injection.
Supplementary Tables S1 - S4 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

Table S1. Top 10 significant molecular terms (MSigDB c2cp; Curated Pathways) enriched in correlated and inversely-anticorrelated genes with tumor purity. Table S2. The GSEA results from individual tumor types. Table S3. Immune cell type-specific genes. Table S4. GSEA of genes with high/low differential correlation coefficients.
Figure S4 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S4. Relationship with the tumor purity, CYT expression and neoantigen abundance.
Supplementary Figure S1. TILs isolated from tolerant, tumor-bearing neu/N mice are profoundly T cell deficient. from A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Authors: Foote Jeremy B. , Kok Marleen , Leatherman James M. , Armstrong Todd D. , Marcinkowski Bridget C. , Ojalvo Laureen S. , Kanne David B. , Jaffee Elizabeth M. , Dubensky Thomas W. , Emens Leisha A.
Published: April 2023

Tumor bearing FVB/N (A) and neu/N (B) mice were evaluated for lymphocytic infiltrate on hematoxylin and eosin stained, paraffin-fixed tumors. CD4+ and CD8+ T cell infiltrates within tumors isolated from FVB (C) and neu/N (D) mice. Data is representative of 2 experiments of 4 - 5 mice/group. * p < 0.05, ** p<0.01, and *** p<0.001, and **** p<0.0001.
Figure S3 from Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types
Authors: Rhee Je-Keun , Jung Yu Chae , Kim Kyu Ryung , Yoo Jinseon , Kim Jeeyoon , Lee Yong-Jae , Ko Yoon Ho , Lee Han Hong , Cho Byoung Chul , Kim Tae-Min
Published: April 2023

S3. Correlation between gene expression and tumor purity estimated across 21 tumor types.
Supplementary S4 from Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Authors: Bartolacci Caterina , Andreani Cristina , Curcio Claudia , Occhipinti Sergio , Massaccesi Luca , Giovarelli Mirella , Galeazzi Roberta , Iezzi Manuela , Tilio Martina , Gambini Valentina , Wang Junbiao , Marchini Cristina , Amici Augusto
Published: April 2023

Evidences of central and peripheral immune tolerance in Î"16HER2 mice
Supplemental Table 2 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Authors: Santini Fernando C. , Rizvi Hira , Plodkowski Andrew J. , Ni Andy , Lacouture Mario E. , Gambarin-Gelwan Maya , Wilkins Olivia , Panora Elizabeth , Halpenny Darragh F. , Long Niamh M. , Kris Mark G. , Rudin Charles M. , Chaft Jamie E. , Hellmann Matthew D.
Published: April 2023

Retreatment Cohort - Initial irAEs: Clinical Characteristics and Features
Supplemental Figure 1 from Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Authors: Santini Fernando C. , Rizvi Hira , Plodkowski Andrew J. , Ni Andy , Lacouture Mario E. , Gambarin-Gelwan Maya , Wilkins Olivia , Panora Elizabeth , Halpenny Darragh F. , Long Niamh M. , Kris Mark G. , Rudin Charles M. , Chaft Jamie E. , Hellmann Matthew D.
Published: April 2023

Time From First Dose of Immunotherapy to Date of The Initial irAE
Supplementary Table 1 from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Authors: Lizotte Patrick H. , Hong Ruey-Long , Luster Troy A. , Cavanaugh Megan E. , Taus Luke J. , Wang Stephen , Dhaneshwar Abha , Mayman Naomi , Yang Aaron , Kulkarni Meghana , Badalucco Lauren , Fitzpatrick Erica , Kao Hsiang-Fong , Kuraguchi Mari , Bittinger Mark , Kirschmeier Paul T. , Gray Nathanael S. , Barbie David A. , Jänne Pasi A.
Published: April 2023

Table 1 compound list
Supplementary Table S2 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

Number of conjugated liposomes
Supplementary Fig S3 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

Additional in vivo data
Supplementary Fig S2 from CAR-T Cells Surface-Engineered with Drug-Encapsulated Nanoparticles Can Ameliorate Intratumoral T-cell Hypofunction
Authors: Siriwon Natnaree , Kim Yu Jeong , Siegler Elizabeth , Chen Xianhui , Rohrs Jennifer A. , Liu Yarong , Wang Pin
Published: April 2023

Additional in vitro data
Supplementary Figures 1 and 2 from Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes
Authors: Horn Lucas A. , Long Tiha M. , Atkinson Ryan , Clements Virginia , Ostrand-Rosenberg Suzanne
Published: April 2023

Supplementary figures 1 & 2
Supplemental Contents and Legends from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Supplemental Contents and Legends
Figure S3 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Individual tumor growth curves; IT antibody + IT agonists
Figure S2 from Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
Authors: Ager Casey R. , Reilley Matthew J. , Nicholas Courtney , Bartkowiak Todd , Jaiswal Ashvin R. , Curran Michael A.
Published: April 2023

Individual tumor growth curves; IP antibody + IT agonists
Figure S7 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Authors: Chan Wing Keung , Kang Siwen , Youssef Youssef , Glankler Erin N. , Barrett Emma R. , Carter Alex M. , Ahmed Elshafa H. , Prasad Aman , Chen Luxi , Zhang Jianying , Benson Don M. , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

A MM NSG mouse model bearing the H929 cell line with the intermediate level of CS1 expression was used to evaluate the anti-MM effect of the CS1-NKG2D biAb
Figure S4 from A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
Authors: Chan Wing Keung , Kang Siwen , Youssef Youssef , Glankler Erin N. , Barrett Emma R. , Carter Alex M. , Ahmed Elshafa H. , Prasad Aman , Chen Luxi , Zhang Jianying , Benson Don M. , Caligiuri Michael A. , Yu Jianhua
Published: April 2023

Effect of CS1-NKG2D biAb on human immune cells
Supplemental Figure Legends from PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
Authors: Goyal Girija , Wong Karrie , Nirschl Christopher J. , Souders Nicholas , Neuberg Donna , Anandasabapathy Niroshana , Dranoff Glenn
Published: April 2023

Legends text
Supplemental Figure 4 from PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
Authors: Goyal Girija , Wong Karrie , Nirschl Christopher J. , Souders Nicholas , Neuberg Donna , Anandasabapathy Niroshana , Dranoff Glenn
Published: April 2023

S4. Dendritic cell populations in the dLNs of vaccinated control and PPAR-γ deficient mice.
Supplemental Figure 3 from PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
Authors: Goyal Girija , Wong Karrie , Nirschl Christopher J. , Souders Nicholas , Neuberg Donna , Anandasabapathy Niroshana , Dranoff Glenn
Published: April 2023

S3. PPAR-γ modulation does not impact selected surface marker expression in human peripheral blood myeloid cells.
Supplemental Figure 1 from PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF
Authors: Goyal Girija , Wong Karrie , Nirschl Christopher J. , Souders Nicholas , Neuberg Donna , Anandasabapathy Niroshana , Dranoff Glenn
Published: April 2023

S1. PPAR-γ modulation does not impact expression of selected surface markers in mouse myeloid cells.
Table S1 from Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
Authors: Nishida Sumiyuki , Ishikawa Takeshi , Egawa Shinichi , Koido Shigeo , Yanagimoto Hiroaki , Ishii Jun , Kanno Yoshihide , Kokura Satoshi , Yasuda Hiroaki , Oba Mari Saito , Sato Maho , Morimoto Soyoko , Fujiki Fumihiro , Eguchi Hidetoshi , Nagano Hiroaki , Kumanogoh Atsushi , Unno Michiaki , Kon Masanori , Shimada Hideaki , Ito Kei , Homma Sadamu , Oka Yoshihiro , Morita Satoshi , Sugiyama Haruo
Published: April 2023

Adverse Events
Movie 2 from Antagonism of IAPs Enhances CAR T-cell Efficacy
Authors: Michie Jessica , Beavis Paul A. , Freeman Andrew J. , Vervoort Stephin J. , Ramsbottom Kelly M. , Narasimhan Vignesh , Lelliott Emily J. , Lalaoui Najoua , Ramsay Robert G. , Johnstone Ricky W. , Silke John , Darcy Phillip K. , Voskoboinik Ilia , Kearney Conor J. , Oliaro Jane
Published: April 2023

Movie S2
Figure S6 from Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Authors: Pfannenstiel Lukas W. , Diaz-Montero C. Marcela , Tian Ye F. , Scharpf Joseph , Ko Jennifer S. , Gastman Brian R.
Published: April 2023

Supplementary Figure 6. B. Histograms demonstrating PD-L1, PD-L2, or galectin-9 (Gal-9) expression on TC-1 tumor cells (purple) as compared to isotype controls (grey). Top, TC-1 tumors growing in mice were harvested and dissociated into a single cell suspension by collagenase/hyaluronidase digestion prior to staining and FACS analysis. Tumor cells were identified by gating on CD45 negative cells. Bottom, TC-1 cells growing in vitro were stained for the indicated proteins.
Figure S4 from Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer
Authors: Pfannenstiel Lukas W. , Diaz-Montero C. Marcela , Tian Ye F. , Scharpf Joseph , Ko Jennifer S. , Gastman Brian R.
Published: April 2023

Supplementary Figure 4 A. Splenocytes from E7-TCRβ transgenic mice were stained with a tetramer for HPV E749-57 (RAHYNIVTF) or a non-specific control tetramer. Cells were gated on CD3+ CD8+. B. Splenocytes from E7-TCRβ mice were stimulated for 7-9 days using HPV E749-57 (RAHYNIVTF) peptide and rhIL-2 (30u/ml). CD8+ T cells were then purfied by magnetic bead purification and used in an in vitro CTL assay using irradiated, labeled or CFSE labeled cells as targets. Ratios are pulsed E7 TCRβ effectors : unlabled control target cells : CFSE-labeled target cells. Wildtype, unlabeled EL4 cells served as negative control targets. C. CD8+ T cells were purified from E7-TCRβ splenocytes using negative magnetic bead selection and transferred into TC-1 tumor bearing mice in the indicated numbers on day 7 after tumor injection. Plot indicates the average tumor size for each group at the indicated timepoints. . D. FACS staining of splenocytes from E7-TCRβ TCR transgenic mice. Arrow indicates the right panel is the CD3+ CD8+ gate from the left panel.
Figures S1-S7 from Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth
Authors: Pacella Ilenia , Cammarata Ilenia , Focaccetti Chiara , Miacci Stefano , Gulino Alessandro , Tripodo Claudio , Ravà Micol , Barnaba Vincenzo , Piconese Silvia
Published: April 2023

Supplementary Figures and Legends
Supplementary Figure S2 from Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis
Authors: Shrimali Rajeev K. , Ahmad Shamim , Verma Vivek , Zeng Peng , Ananth Sudha , Gaur Pankaj , Gittelman Rachel M. , Yusko Erik , Sanders Catherine , Robins Harlan , Hammond Scott A. , Janik John E. , Mkrtichyan Mikayel , Gupta Seema , Khleif Samir N.
Published: April 2023

Effects of the combination therapy of anti-OX40 and anti-PD-1 Abs with tumor vaccine on spleen and tumor T-cell infiltration and clonality.
Table S2 from Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Authors: Lewin Jeremy , Davidson Scott , Anderson Nathaniel D. , Lau Beatrice Y. , Kelly Jacalyn , Tabori Uri , Salah Samer , Butler Marcus O. , Aung Kyaw L. , Shlien Adam , Dickson Brendan C. , Abdul Razak Albiruni R.
Published: April 2023

Length values for microsatellite loci
Supplementary Table 1 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
Authors: Ghonime Mohammed G. , Cassady Kevin A.
Published: April 2023

Supplementary Table 1: Nomenclature of oncolytic HSV-1 and their genetics
Supplementary Figure 5 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
Authors: Ghonime Mohammed G. , Cassady Kevin A.
Published: April 2023

Supplementary Figure 5: 67C-4 tumor cells express EphA2 and control peptide doesn't induce CD8 T cell activation
Supplementary Figure 4 from Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy
Authors: Ghonime Mohammed G. , Cassady Kevin A.
Published: April 2023

Supplementary Figure 4: Virus treatment increases CD8 activation in the periphery (D3) and combination therapy maintains the activation (D5)
Figure S3 from Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Authors: Lewin Jeremy , Davidson Scott , Anderson Nathaniel D. , Lau Beatrice Y. , Kelly Jacalyn , Tabori Uri , Salah Samer , Butler Marcus O. , Aung Kyaw L. , Shlien Adam , Dickson Brendan C. , Abdul Razak Albiruni R.
Published: April 2023

Immunohistochemistry in MLH1, MSH2, MSH6 and PMS2 showed intact IHC expression in Patient 2 (magnification: 200x).
Supplementary Figures 1-8 from ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis
Authors: Sidhom John-William , Bessell Catherine A. , Havel Jonathan J. , Kosmides Alyssa , Chan Timothy A. , Schneck Jonathan P.
Published: April 2023

S1. In order to set thresholds for motif detection, two variables were optimized on a Naïve Adult B6 CD8 Repertoire (taken from Adaptive Biotechnologies ImmunoSeq Sample Data). Motif detection was completed across a range of phylogenetic distances and frequency thresholds and number of motifs detected was monitored. Since our analysis was looking for dominant motifs above what is present in an unexpanded population, we chose a frequency threshold of 0.03 and Phylogenetic Distance threshold of 0.35, at which 0 motifs were detected in Naïve B6 background. S2. A) FACS analysis of antigen-specific CD8 T cells on D7 in Naïve and Tumor-bearing lymphoid organs. B) ICS staining of antigen-specific CD8 T Cells confirming specificity and functionality. C) Comparison of Dimer+ and TNF+ CD8. D) Antigen-specific CD8 T cells staining from splenic CD8 T cells directly ex vivo compared to unloaded Kb-Ig staining. N = 3, Statistical 2-tailed T-test. S3. V-beta usage for Naïve Kb-SIY & Kb-TRP2 Response S4. V-beta usage for Tumor-Bearing Kb-SIY & Kb-TRP2 Response in Various Lymphoid Organs S5. In order to determine number of tumor-infiltrating lymphocytes that were sequenced for each patient, Adaptive reported amount of total DNA in nanograms that underwent sequencing and based on the assumption of 6.5pgDNA per cell, we were able to calculate the number of total cells that underwent sequencing. Furthermore, Adaptive calculated a %TIL metric based on number of non-recombined to recombined sequence reads. With this information, we were able to deduce the number of starting lymphocytes that were sequenced for each patient. S6. Calculation of TCR Diversity Score S7. Duplicates of Murine Experiments S8: ImmunoMap Graphical User Interface & Instructions for Use
Figure S4 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells
Authors: Clancy-Thompson Eleanor , Ali Lestat , Bruck Patrick T. , Exley Mark A. , Blumberg Richard S. , Dranoff Glenn , Dougan Michael , Dougan Stephanie K.
Published: April 2023

S4: CD1d knockout mice show a significant contribution of the costimulatory effects of LBW-242 on cytokine production by CD4+ T cells.
Table S1 from Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Authors: Witt Kristina , Ligtenberg Maarten A. , Conti Laura , Lanzardo Stefania , Ruiu Roberto , Wallmann Tatjana , Tufvesson-Stiller Helena , Chambers Benedict J. , Rolny Charlotte , Lladser Alvaro , Lundqvist Andreas , Cavallo Federica , Kiessling Rolf
Published: April 2023

Summary of all antibodies.
Figure S5 from Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma
Authors: Witt Kristina , Ligtenberg Maarten A. , Conti Laura , Lanzardo Stefania , Ruiu Roberto , Wallmann Tatjana , Tufvesson-Stiller Helena , Chambers Benedict J. , Rolny Charlotte , Lladser Alvaro , Lundqvist Andreas , Cavallo Federica , Kiessling Rolf
Published: April 2023

Tumor multiplicity in BALB-neuT mice.
Supplemental Figure Legends from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Authors: Richman Sarah A. , Nunez-Cruz Selene , Moghimi Babak , Li Lucy Z. , Gershenson Zachary T. , Mourelatos Zissimos , Barrett David M. , Grupp Stephan A. , Milone Michael C.
Published: April 2023

Supplemental Figure Legends
Supplementary Table 1 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
Authors: Eissmann Moritz F. , Dijkstra Christine , Wouters Merridee A. , Baloyan David , Mouradov Dmitri , Nguyen Paul M. , Davalos-Salas Mercedes , Putoczki Tracy L. , Sieber Oliver M. , Mariadason John M. , Ernst Matthias , Masson Frederick
Published: April 2023

Suppl Table 1. Oligonucleotide Sequences
Figure S4 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Authors: Richman Sarah A. , Nunez-Cruz Selene , Moghimi Babak , Li Lucy Z. , Gershenson Zachary T. , Mourelatos Zissimos , Barrett David M. , Grupp Stephan A. , Milone Michael C.
Published: April 2023

CD8 IHC on indicated brain structures from mice receiving E101K CAR T cells.
Figure S2 from High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
Authors: Richman Sarah A. , Nunez-Cruz Selene , Moghimi Babak , Li Lucy Z. , Gershenson Zachary T. , Mourelatos Zissimos , Barrett David M. , Grupp Stephan A. , Milone Michael C.
Published: April 2023

Comparison of dissociation of GD2 and E101K IgG. SY5Y cells were incubated with mouse-IgG containing the variable domains from either the GD2 or E101K scFvs. Antibody was then allowed to dissociate in room temperature buffer for the indicated number of seconds, and bound antibody was then detected by flow cytometry using AF-647 labeled secondary antibody.
Supplementary Figure S3 from Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
Authors: Eissmann Moritz F. , Dijkstra Christine , Wouters Merridee A. , Baloyan David , Mouradov Dmitri , Nguyen Paul M. , Davalos-Salas Mercedes , Putoczki Tracy L. , Sieber Oliver M. , Mariadason John M. , Ernst Matthias , Masson Frederick
Published: April 2023

Fig S3. St2 is not expressed by Lgr5+ stem cells within the colon.
Supplementary Table and Figures from PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy
Authors: Chowdhury Partha S. , Chamoto Kenji , Kumar Alok , Honjo Tasuku
Published: April 2023

Table S1, Figure S1, Figure S2. Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
Table S5 from Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Authors: Lisberg Aaron , Tucker D. Andrew , Goldman Jonathan W. , Wolf Brian , Carroll James , Hardy Ariana , Morris Karolyn , Linares Paulina , Adame Carlos , Spiegel Marshall L. , Wells Courtney , McKenzie Jordan , Ledezma Blanca , Mendenhall Melody , Abarca Phillip , Bornazyan Krikor , Hunt Jaime , Moghadam Nima , Chong Natalie , Nameth Danielle , Marx Caitlin , Madrigal John , Vangala Sitaram , Shaverdian Narek , Elashoff David , Garon Edward B.
Published: April 2023

Supplementary Table S5a: Cox proportional hazards models for progression-free survival (PFS) with number of treatment related select adverse events included as a time-varying covariate. Listed are results from both unadjusted models and adjusted models. Hazard ratio estimates marked '(+1)' correspond to the incremental effect of a unit increase in the relevant predictor.
Table S3 from CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma
Authors: Samaniego Rafael , Gutiérrez-González Alejandra , Gutiérrez-Seijo Alba , Sánchez-Gregorio Sandra , García-Giménez Jorge , Mercader Enrique , Márquez-Rodas Iván , Avilés José Antonio , Relloso Miguel , Sánchez-Mateos Paloma
Published: April 2023

Supplementary Table S3. Stromal-CCL20 association with clinicopathological features.
Figure S1 from NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
Authors: Witalisz-Siepracka Agnieszka , Gotthardt Dagmar , Prchal-Murphy Michaela , Didara Zrinka , Menzl Ingeborg , Prinz Daniela , Edlinger Leo , Putz Eva Maria , Sexl Veronika
Published: April 2023

Quantification of NK cell numbers and their maturation stages from Fig. 1
Supplementary Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
Authors: McKay Rana R. , Bossé Dominick , Xie Wanling , Wankowicz Stephanie A.M. , Flaifel Abdallah , Brandao Raphael , Lalani Aly-Khan A. , Martini Dylan J. , Wei Xiao X. , Braun David A. , Van Allen Eliezer , Castellano Daniel , De Velasco Guillermo , Wells J. Connor , Heng Daniel Y. , Fay Andre P. , Schutz Fabio A. , Hsu JoAnn , Pal Sumanta K. , Lee Jae Lyun , Hsieh James J. , Harshman Lauren C. , Signoretti Sabina , Motzer Robert J. , Feldman Darren , Choueiri Toni K.
Published: April 2023

Includes: Table 1S. Baseline patient and disease characteristics. Table 2S. Tumor mutation burden status. Table 3S. PDL1 expression data. Figure 1S. Overall survival for the total cohort.
Supplementary Data from A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity
Authors: Ma Hayley S. , Poudel Bibhav , Torres Evanthia Roussos , Sidhom John-William , Robinson Tara M. , Christmas Brian , Scott Blake , Cruz Kayla , Woolman Skylar , Wall Valerie Z. , Armstrong Todd , Jaffee Elizabeth M.
Published: April 2023

Supplementary Table S1, Supplementary Figures S1-7
Figure 3S from Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia
Authors: Vicioso Yorleny , Gram Hermann , Beck Rose , Asthana Abhishek , Zhang Keman , Wong Derek P. , Letterio John , Parameswaran Reshmi
Published: April 2023

Supp. Fig. 3 Differential NK cells receptor expression A, Expression of activating and inhibitory receptors in NK cells expanded from the indicated healthy donors (mean {plus minus} SD of 3 technical replicates). B, Expression of HLAE and MICA/B on the indicated ALL patient samples analyzed by flow cytometry (mean {plus minus} SD of 3 technical replicates). C, comparison of PT-1 specific lysis using the indicated effector to target ratios (mean {plus minus} SD of 3 technical replicates). D, Comparison of ADCC using NK cells from 4 healthy donors as determined by annexin v+ and Propidium Iodide+ cells by flow cytometry. Experiments done with 3 technical replicates.
Supplementary Figure 6 from Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
Authors: Hutmacher Cornelia , Gonzalo Núñez Nicolás , Liuzzi Anna Rita , Becher Burkhard , Neri Dario
Published: April 2023

Multiparameter flow cytometric analysis of MC38 draining LN
Supplementary Data from Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages
Authors: Limagne Emeric , Thibaudin Marion , Nuttin Lisa , Spill Aodrenn , Derangère Valentin , Fumet Jean-David , Amellal Nadia , Peranzoni Elisa , Cattan Valérie , Ghiringhelli François
Published: April 2023

Supplementary figures
Supplementary Figure 5 from Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
Authors: Hutmacher Cornelia , Gonzalo Núñez Nicolás , Liuzzi Anna Rita , Becher Burkhard , Neri Dario
Published: April 2023

Multiparameter flow cytometric analysis of MC38 tumors
Supplementary Figure 3 from Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
Authors: Hutmacher Cornelia , Gonzalo Núñez Nicolás , Liuzzi Anna Rita , Becher Burkhard , Neri Dario
Published: April 2023

Supplementary flow cytometry data of CT26 tumors
Supplementary Figure 2 from Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
Authors: Hutmacher Cornelia , Gonzalo Núñez Nicolás , Liuzzi Anna Rita , Becher Burkhard , Neri Dario
Published: April 2023

Rechallenge
Supplementary Table 2 from Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
Authors: Cavalleri Tommaso , Bianchi Paolo , Basso Gianluca , Celesti Giuseppe , Grizzi Fabio , Bossi Paola , Greco Luana , Pitrone Calogero , Valtorta Emanuele , Mauri Gianluca , Truini Mauro , Dall'Olio Filippo Gustavo , Brandi Giovanni , Sartore-Bianchi Andrea , Ricciardiello Luigi , Torri Valter , Rimassa Lorenza , Siena Salvatore , Mantovani Alberto , Malesci Alberto , Laghi Luigi
Published: April 2023

Predictors of post-surgical recurrence in 413 CRC patients with stage II/III CRC.
Supplementary Table 1 from Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
Authors: Cavalleri Tommaso , Bianchi Paolo , Basso Gianluca , Celesti Giuseppe , Grizzi Fabio , Bossi Paola , Greco Luana , Pitrone Calogero , Valtorta Emanuele , Mauri Gianluca , Truini Mauro , Dall'Olio Filippo Gustavo , Brandi Giovanni , Sartore-Bianchi Andrea , Ricciardiello Luigi , Torri Valter , Rimassa Lorenza , Siena Salvatore , Mantovani Alberto , Malesci Alberto , Laghi Luigi
Published: April 2023

Densities of FoxP3+ and CD3+ TILs in 413 stage II-III CRC, by clinical-pathological variables.
Supplementary Figure 1 from Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
Authors: Cavalleri Tommaso , Bianchi Paolo , Basso Gianluca , Celesti Giuseppe , Grizzi Fabio , Bossi Paola , Greco Luana , Pitrone Calogero , Valtorta Emanuele , Mauri Gianluca , Truini Mauro , Dall'Olio Filippo Gustavo , Brandi Giovanni , Sartore-Bianchi Andrea , Ricciardiello Luigi , Torri Valter , Rimassa Lorenza , Siena Salvatore , Mantovani Alberto , Malesci Alberto , Laghi Luigi
Published: April 2023

ROC curves for densities of FoxP3+ and CD3+ TILs as predictors of postsurgical recurrence in patients with stage II MSS CRC, validation set.
Supplementary Figures and Tables from Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells
Authors: Di Lorenzo Biagio , Simões André E. , Caiado Francisco , Tieppo Paola , Correia Daniel V. , Carvalho Tânia , da Silva Maria Gomes , Déchanet-Merville Julie , Schumacher Ton N. , Prinz Immo , Norell Haakan , Ravens Sarina , Vermijlen David , Silva-Santos Bruno
Published: April 2023

Supplementary Figures 1-5 and tables 1-3
Movie S1 Legend from Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Authors: Xiong Huizhong , Mittman Stephanie , Rodriguez Ryan , Pacheco-Sanchez Patricia , Moskalenko Marina , Yang Yagai , Elstrott Justin , Ritter Alex T. , Müller Sören , Nickles Dorothee , Arenzana Teresita L. , Capietto Aude-Hélène , Delamarre Lélia , Modrusan Zora , Rutz Sascha , Mellman Ira , Cubas Rafael
Published: April 2023

Cytotoxicity assay with sorted PD1+LAG3+TIM3+ CD8 T cells
Table S7 from The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes
Authors: Pfannstiel Carolin , Strissel Pamela L. , Chiappinelli Katherine B. , Sikic Danijel , Wach Sven , Wirtz Ralph M. , Wullweber Adrian , Taubert Helge , Breyer Johannes , Otto Wolfgang , Worst Thomas , Burger Maximilian , Wullich Bernd , Bolenz Christian , Fuhrich Nicole , Geppert Carol I. , Weyerer Veronika , Stoehr Robert , Bertz Simone , Keck Bastian , Erlmeier Franziska , Erben Philipp , Hartmann Arndt , Strick Reiner , Eckstein Markus
Published: April 2023

Antigen presenting cell signature TCGA: Full table of included genes.
Table S4 from Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma
Authors: Xiang Handan , Ramil Carlo P. , Hai Josephine , Zhang Chunsheng , Wang Huijun , Watkins Amanda A. , Afshar Roshi , Georgiev Peter , Sze Marc A. , Song Xuelei S. , Curran Patrick J. , Cheng Mangeng , Miller J. Richard , Sun Dongyu , Loboda Andrey , Jia Yanlin , Moy Lily Y. , Chi An , Brandish Philip E.
Published: April 2023

Supplementary table 4
Table S3 from The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes
Authors: Pfannstiel Carolin , Strissel Pamela L. , Chiappinelli Katherine B. , Sikic Danijel , Wach Sven , Wirtz Ralph M. , Wullweber Adrian , Taubert Helge , Breyer Johannes , Otto Wolfgang , Worst Thomas , Burger Maximilian , Wullich Bernd , Bolenz Christian , Fuhrich Nicole , Geppert Carol I. , Weyerer Veronika , Stoehr Robert , Bertz Simone , Keck Bastian , Erlmeier Franziska , Erben Philipp , Hartmann Arndt , Strick Reiner , Eckstein Markus
Published: April 2023

CIBERSORT - Spearman rank correlations between predicted immune cell populations in the TCGA cohort.